Alumis Financial Ratios
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.16+0.19 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alumis ratio analysis
Alumis earned a net margin of -1011.7% in FY 2025. Return on equity reached -80.8%, meaning Alumis generated -0.81 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Alumis financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 31.66 | — | — |
| Price / book | 2.53 | 0.92 | — |
| Operating margin | -1,886.9% | — | — |
| Net margin | -1,011.7% | — | — |
| Free cash flow margin | -1,539.2% | — | — |
| Return on equity (ROE) | -80.8% | -113.1% | — |
| Return on assets (ROA) | -59.1% | -86.3% | -173.0% |
| Current ratio | 4.34 | 6.01 | 2.56 |